3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Skin Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
51
Ipilimumab
50
Cyclophosphamide
43
Nivolumab
41
aldesleukin
30
Interleukin-2
23
Vemurafenib
20
fludarabine
19
Temozolomide
18
fludarabine phosphate
15
dabrafenib
15
trametinib
12
spartalizumab
10
Radiotherapy
10
Radiosurgery
10
Dacarbazine
10
CTLA-4 Antigen
10
cobimetinib
9
binimetinib
9
poly ICLC
7
encorafenib
7
Paclitaxel
7
atezolizumab
6
Introns
6
Biopsy
6
montanide ISA 51
5
Carboplatin
5
epacadostat
4
MART-1 Antigen
4
Interferon alpha-2
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Melanoma
×
Interleukins
×
Clear all
NCT01856023
2023-12-05
PROCLIVITY02
Clinigen, Inc.
Phase 4
Terminated
29 enrolled
9 charts